You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
OSU 6162 hydrochloride
Biological Activity for OSU 6162 hydrochloride
OSU 6162 hydrochloride is a dopamine stabilizer; lacks high affinity for various neuroreceptors in vitro (Ki values are 447 and 1305 nM for D2 and D3 receptors respectively and > 1 μM for other targets). Exhibits high D2 receptor occupancy in vivo; highly active on dopamine synthesis and turnover. Induces stabilizing effects on psychomotor function in behavioral tests without inducing hypolocomotion or catalepsy.
Sold for research purposes under agreement from Pfizer Inc.
Compound Libraries for OSU 6162 hydrochloride
Technical Data for OSU 6162 hydrochloride
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for OSU 6162 hydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for OSU 6162 hydrochloride
The following data is based on the product molecular weight 317.87. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.15 mL||15.73 mL||31.46 mL|
|5 mM||0.63 mL||3.15 mL||6.29 mL|
|10 mM||0.31 mL||1.57 mL||3.15 mL|
|50 mM||0.06 mL||0.31 mL||0.63 mL|
Product Datasheets for OSU 6162 hydrochloride
References for OSU 6162 hydrochloride
References are publications that support the biological activity of the product.
Nichols et al (2002) PNU-96391A (OSU6162) antagonizes the development of behavioural sensitization induced by DA agonists in a rat model for Parkinson's disease. Neuropharmacology 43 817 PMID: 12384167
Natesan et al (2006) The DA stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potentia J.Pharmacol.Exp.Ther. 318 810 PMID: 16648369
Rung et al (2005) The DArgic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog.Neuro-Psychopharm.Biol.Psychiat. 29 833
If you know of a relevant reference for OSU 6162 hydrochloride, please let us know.
Keywords: OSU 6162 hydrochloride, OSU 6162 hydrochloride supplier, Dopamine, stabilizer, Dopaminergic, Receptors, OSU6162, hydrochloride, PNU96391, D2, receptor, PNU, 96391, Dopaminergic-Related, 2599, Tocris Bioscience
Citations for OSU 6162 hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for OSU 6162 hydrochloride. Do you know of a great paper that uses OSU 6162 hydrochloride from Tocris? Please let us know.
Reviews for OSU 6162 hydrochloride
There are currently no reviews for this product. Be the first to review OSU 6162 hydrochloride and earn rewards!
Have you used OSU 6162 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.